JP2017510641A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510641A5
JP2017510641A5 JP2017502932A JP2017502932A JP2017510641A5 JP 2017510641 A5 JP2017510641 A5 JP 2017510641A5 JP 2017502932 A JP2017502932 A JP 2017502932A JP 2017502932 A JP2017502932 A JP 2017502932A JP 2017510641 A5 JP2017510641 A5 JP 2017510641A5
Authority
JP
Japan
Prior art keywords
cancer
nitrogen
independently selected
oxygen
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017502932A
Other languages
English (en)
Japanese (ja)
Other versions
JP6757312B2 (ja
JP2017510641A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/022841 external-priority patent/WO2015148854A1/en
Publication of JP2017510641A publication Critical patent/JP2017510641A/ja
Publication of JP2017510641A5 publication Critical patent/JP2017510641A5/ja
Application granted granted Critical
Publication of JP6757312B2 publication Critical patent/JP6757312B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017502932A 2014-03-27 2015-03-26 置換インドールmcl−1阻害剤 Active JP6757312B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461971023P 2014-03-27 2014-03-27
US61/971,023 2014-03-27
PCT/US2015/022841 WO2015148854A1 (en) 2014-03-27 2015-03-26 Substituted indole mcl-1 inhibitors

Publications (3)

Publication Number Publication Date
JP2017510641A JP2017510641A (ja) 2017-04-13
JP2017510641A5 true JP2017510641A5 (OSRAM) 2018-05-17
JP6757312B2 JP6757312B2 (ja) 2020-09-16

Family

ID=54196421

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502932A Active JP6757312B2 (ja) 2014-03-27 2015-03-26 置換インドールmcl−1阻害剤

Country Status (7)

Country Link
US (3) US10533010B2 (OSRAM)
EP (1) EP3122353B1 (OSRAM)
JP (1) JP6757312B2 (OSRAM)
CN (1) CN106456602B (OSRAM)
AU (1) AU2015235944B2 (OSRAM)
CA (1) CA2943815C (OSRAM)
WO (1) WO2015148854A1 (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2943815C (en) 2014-03-27 2023-04-04 Vanderbilt University Substituted indole mcl-1 inhibitors
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
US11306107B2 (en) 2016-02-25 2022-04-19 Amgen Inc. Compounds that inhibit MCL-1 protein
EP4292662A3 (en) * 2016-03-04 2024-02-21 Vanderbilt University Substituted indole mcl-1 inhibitors
MX386103B (es) 2016-04-22 2025-03-18 Astrazeneca Ab Inhibidores de mcl-1 y metodos de uso de los mismos.
EP3458459B1 (en) 2016-05-19 2022-04-27 Bayer Aktiengesellschaft Macrocyclic indole derivatives
WO2017198341A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Mcl−1タンパク質を阻害する化合物
TW201841888A (zh) * 2017-04-30 2018-12-01 財團法人生物技術開發中心 一種抗癌幹性之藥物
WO2019040511A1 (en) * 2017-08-22 2019-02-28 University Of Maryland Batimore DOUBLE INHIBITORS OF BCL-2 AND HDM2 FAMILIES BY CO-MIMETTISM OF ALPHA BH3 AND P53 PROPELLERS
AR113887A1 (es) 2017-11-17 2020-06-24 Bayer Ag Derivados de indol macrocíclicos sustituidos con cloro
EP3710450A1 (en) 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
WO2019096907A1 (en) 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Aryl annulated macrocyclic indole derivatives
UY37973A (es) 2017-11-17 2019-06-28 Bayer Ag Derivados de indol macrocíclicos
WO2019096909A1 (en) 2017-11-17 2019-05-23 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer
UY37971A (es) 2017-11-17 2019-06-28 Bayer Ag Derivados de indol macrocíclicos sustituidos
CN109988151B (zh) * 2017-12-29 2021-04-23 北京赛特明强医药科技有限公司 一种炔类化合物、制备方法及其应用
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
CN108251104B (zh) * 2018-02-27 2019-11-05 山东大学 一种取代吲哚-2-羧酸类Bcl-2小分子荧光探针及其应用
KR102732008B1 (ko) * 2018-05-14 2024-11-20 길리애드 사이언시즈, 인코포레이티드 Mcl-1 억제제
EP3810573A4 (en) 2018-06-25 2021-12-08 Suzhou Mednes Pharma Tech Co., Ltd. COMPOUNDS AND METHODS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE HEDGEHOG ROUTE
BR112021005655A2 (pt) 2018-09-27 2021-06-29 Pierre Fabre Medicament ligantes à base de sulfomaleimida e conjugados correspondentes
US11691989B2 (en) 2018-11-22 2023-07-04 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic indoles as Mcl-1 inhibitors
WO2020147802A1 (en) 2019-01-18 2020-07-23 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic spiroethers as mcl-1 inhibitors
EP3969457B1 (en) 2019-05-17 2025-08-13 The Broad Institute Inc. Methods of preparing macrocyclic indoles
WO2021092061A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Combination treatment for senescence-associated diseases
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
AU2023389065A1 (en) * 2022-12-06 2025-06-19 Captor Therapeutics S.A. Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
WO2024123195A1 (en) * 2022-12-06 2024-06-13 Captor Therapeutics S.A. Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
WO2025104079A1 (en) * 2023-11-17 2025-05-22 Helmholtz-Zentrum für Infektionsforschung GmbH Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703053A (en) 1985-10-28 1987-10-27 Warner-Lambert Company Benzothiophenes and benzofurans and antiallergic use thereof
GB8531612D0 (en) 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
US4994477A (en) * 1988-03-24 1991-02-19 Abbott Laboratories Heterocyclic renin inhibitors
DE4128015A1 (de) 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US5436264A (en) * 1993-08-19 1995-07-25 Syntex (U.S.A.) Inc. N-aryloxyalkyl tryptamine α1 -adrenergic receptor antagonists
JP3739432B2 (ja) 1994-02-25 2006-01-25 ダイセル化学工業株式会社 オゾン開裂反応
WO1997042188A1 (en) 1996-05-08 1997-11-13 Kumiai Chemical Industry Co., Ltd. Indolyl-substituted uracil derivatives and herbicides comprising them as active ingredients
CA2265853C (en) 1996-09-12 2010-08-03 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1.beta.-converting enzyme (ice)/ced-3 family inhibitors
FR2761073B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
FR2761070B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
AU2002211901A1 (en) 2000-10-10 2002-04-22 Smithkline Beecham Corporation Substituted indoles, pharmaceutical compositions containing such indoles and their use as PPAR-gamma binding agents
FR2827287B1 (fr) 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2005056522A2 (en) 2003-12-04 2005-06-23 National Health Research Institutes Indole compounds
US7429611B2 (en) 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
WO2007112322A2 (en) 2006-03-28 2007-10-04 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
PL2094662T3 (pl) 2006-12-14 2012-09-28 Astellas Pharma Inc Związki oparte na policyklicznych kwasach użyteczne jako antagoniści rCRTH2 oraz jako środki przeciwalergiczne
JP5496877B2 (ja) 2007-04-16 2014-05-21 アッヴィ・インコーポレイテッド 7−置換インドールMcl−1阻害薬
CA2951295C (en) * 2007-04-16 2020-04-28 Abbvie Inc. 7-nonsubstituted indole mcl-1 inhibitors
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
EP2161266A1 (en) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Benzofuran derivatives as orexin receptor antagonists
EP3124494B1 (en) 2008-12-09 2019-06-19 Dana-Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
FR2961393B1 (fr) 2010-06-16 2013-02-15 Oreal Procede de coloration capillaire a partir d'une composition comprenant au moins un compose indolique ou une indolinique, un sel metallique, du peroxyde d'hydrogene et un agent alcalinisant
CN103201263A (zh) 2010-09-08 2013-07-10 匹兹堡高等教育联邦体系大学 p53-Mdm2拮抗剂
AU2012226398B9 (en) 2011-03-06 2017-04-13 Merck Serono S.A. Low fucose cell lines and uses thereof
CN103974956B (zh) 2011-11-29 2016-07-06 南京奥昭生物科技有限公司 作为hdac6抑制剂和用作抗肿瘤剂的杂环酰胺化合物
WO2013112878A1 (en) * 2012-01-26 2013-08-01 The Penn State Research Foundation Mcl-1 modulating compositions
WO2014047427A2 (en) 2012-09-21 2014-03-27 Vanderbilt University Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
US10005728B2 (en) 2013-08-28 2018-06-26 Vanderbilt University Substituted indole Mcl-1 inhibitors
CA2943815C (en) 2014-03-27 2023-04-04 Vanderbilt University Substituted indole mcl-1 inhibitors
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
EP4292662A3 (en) 2016-03-04 2024-02-21 Vanderbilt University Substituted indole mcl-1 inhibitors

Similar Documents

Publication Publication Date Title
JP2017510641A5 (OSRAM)
CN103200822B (zh) 2-取代-8-烷基-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-腈和其应用
CN110776507B (zh) Bcl-2抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途
CN110772639B (zh) Bcl-2抑制剂与MDM2抑制剂的组合产品及其在预防和/或治疗疾病中的用途
JP7028809B2 (ja) コルテキソロン17α-バレレートを含む腫瘍治療に用いるための組成物
CN105163584B (zh) 用于治疗癌症的化合物
JP2019516759A5 (OSRAM)
JP2013529200A5 (OSRAM)
JP2013526540A5 (OSRAM)
RU2019101220A (ru) Кристаллические формы соединения триазолопиримидина
JP2013529199A5 (OSRAM)
JP2013526538A5 (OSRAM)
EP3716978B1 (en) N-(phenyl)-n'-(6-quinoxalinyl)-urea derivatives as ikkb inhibitors for the treatment of cancer
JP2019529475A5 (OSRAM)
AU2016301212A1 (en) Inhibitors of ACK1/TNK2 tyrosine kinase
CN104470509A (zh) 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途
CN104755455B (zh) 可用于治疗癌症的巨大戟醇衍生化合物
CN102573833A (zh) 癌细胞凋亡
ES2779465T3 (es) Compuesto para el tratamiento o la prevención del cáncer de mama
Banik et al. Novel 6, 12-disubstituted chrysene as potent anticancer agent: synthesis, in vitro and in vivo study
TW202406903A (zh) 聯芳組成物和調控激酶級聯之方法
CN107638426B (zh) 噻唑类化合物在制备治疗肿瘤的药物中的用途
JP2020533399A (ja) 新規低分子化合物
TW201231470A (en) 4-anilinofuro[2,3-b]quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same
TWI594982B (zh) 低細胞毒性血管阻斷劑